First European sales of generic Tiotropium bromide 18 µg DPI, developed by Phargentis
(November 10, 2021) Tiotropium bromide 18 µg Dry Powder Inhaler developed by Phargentis has been launched in Europe. It is the first generic product approved in the EU with precisely the same strength and same delivered dose as Spiriva®Handihaler®, the global first-line treatment for COPD. This generic equivalent has been delivered to the UK, Norway, Spain and the Netherlands, with formal pricing and substitution agreements agreed within those markets. Global turnover for Spiriva®Handihaler® in 2020 exceeded 2.5 bUSD (IQVIA).In May 2021 the generic Tiotropium bromide 18µg DPI, developed by